ZA953537B - Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration - Google Patents

Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration

Info

Publication number
ZA953537B
ZA953537B ZA953537A ZA953537A ZA953537B ZA 953537 B ZA953537 B ZA 953537B ZA 953537 A ZA953537 A ZA 953537A ZA 953537 A ZA953537 A ZA 953537A ZA 953537 B ZA953537 B ZA 953537B
Authority
ZA
South Africa
Prior art keywords
prosthesis
acid derivatives
pct
migration
loosening
Prior art date
Application number
ZA953537A
Other languages
English (en)
Inventor
Allen Edward Goodship
John Kenwright
Jonathan Green
Original Assignee
Ciba Geigy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy filed Critical Ciba Geigy
Publication of ZA953537B publication Critical patent/ZA953537B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Dental Preparations (AREA)
ZA953537A 1994-05-04 1995-05-03 Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration ZA953537B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9408775A GB9408775D0 (en) 1994-05-04 1994-05-04 Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration

Publications (1)

Publication Number Publication Date
ZA953537B true ZA953537B (en) 1995-11-06

Family

ID=10754497

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA953537A ZA953537B (en) 1994-05-04 1995-05-03 Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration

Country Status (18)

Country Link
US (1) US5965547A (de)
EP (1) EP0758241B1 (de)
JP (1) JPH09512816A (de)
AT (1) ATE218350T1 (de)
AU (1) AU693541B2 (de)
DE (1) DE69526937T2 (de)
DK (1) DK0758241T3 (de)
ES (1) ES2177642T3 (de)
FI (1) FI118590B (de)
GB (1) GB9408775D0 (de)
HU (1) HUT74984A (de)
IL (1) IL113566A (de)
NO (1) NO310057B1 (de)
NZ (1) NZ283430A (de)
PT (1) PT758241E (de)
TW (1) TW458779B (de)
WO (1) WO1995030421A1 (de)
ZA (1) ZA953537B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
US6117856A (en) * 1996-02-14 2000-09-12 Binderman; Itzhak Topical bisphosphonates for prevention of bone resorption
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
GB2336311A (en) * 1998-04-15 1999-10-20 Merck & Co Inc Bisphosphonate Dosing Regimen
US6137012A (en) 1998-10-13 2000-10-24 E. I. Du Pont De Nemours And Company Phosphole and diphosphole ligands for catalysis
TR200101546T2 (tr) * 1998-12-04 2001-11-21 Roche Diagnostics Gmbh İç-protezlerde kemik entegrasyonunu iyileştirmek üzere ibandronat kullanılması.
JP2002536123A (ja) * 1999-02-09 2002-10-29 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 抗吸収性骨セメントならびに同種、自家、および異種骨移植片
US6692758B1 (en) * 1999-08-02 2004-02-17 Toray Industries, Inc. Insertion stabilizers for implants
AUPQ232599A0 (en) * 1999-08-19 1999-09-09 Royal Alexandra Hospital For Children, The Drug for treating fractures
ES2394211T3 (es) * 2000-06-20 2013-01-23 Novartis Ag Procedimiento de administración de bifosfonatos
SI1591122T1 (sl) 2000-06-20 2013-02-28 Novartis Ag Postopek za aplikacijo bisfosfonatov
WO2002004038A1 (en) * 2000-07-12 2002-01-17 Hopital Orthopedique De La Suisse Romande Active biocoating for bone implant
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
CA2347330C (en) * 2001-05-10 2002-03-12 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
WO2003095029A1 (en) * 2002-05-10 2003-11-20 F. Hoffmann-La Roche Ag Bisphosphonic acid for the treatment and prevention of osteoporosis
WO2004024166A1 (en) * 2002-09-16 2004-03-25 Novartis Ag Method for preventing or reducing secondary fractures after hip fracture
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
AR064262A1 (es) * 2006-11-17 2009-03-25 Besins Healthcare Composiciones farmaceuticas liquidas que comprenden un compuesto bisfosfonato
EP1958649A1 (de) * 2007-02-14 2008-08-20 Graftys Injizierbarer Kalzium-Phospat-Zement zur Freisetzung eines Knochenschwund-Inhibitors
EP2136814A4 (de) * 2007-03-21 2012-05-30 Univ Duke Medikationskits und formulierungen zur verhütung, behandlung oder reduzierung von sekundären frakturen nach einer vorhergehenden fraktur
US20100317859A1 (en) * 2007-05-16 2010-12-16 Actavis Group Ptc Ehf Process for the Preparation of Risedronate Sodium
CN102639137A (zh) 2009-09-01 2012-08-15 杜克大学 双膦酸类组合物及其治疗心力衰竭的方法
US8882740B2 (en) 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
WO2013074587A1 (en) 2011-11-16 2013-05-23 Duke University Bishophonate compositions and methods for treating and/or reducing cardiac dysfunction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2405254C2 (de) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
US4639338A (en) * 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
DE3776880D1 (de) * 1986-11-21 1992-04-02 Ciba Geigy Ag Neue substituierte alkandiphosphonsaeuren.
JPH05163150A (ja) * 1991-05-13 1993-06-29 E R Squibb & Sons Inc アテローム性動脈硬化症の抑制・治療剤
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices

Also Published As

Publication number Publication date
EP0758241B1 (de) 2002-06-05
FI118590B (fi) 2008-01-15
TW458779B (en) 2001-10-11
DE69526937D1 (de) 2002-07-11
AU2146695A (en) 1995-11-29
ATE218350T1 (de) 2002-06-15
IL113566A0 (en) 1995-08-31
DK0758241T3 (da) 2002-09-23
EP0758241A1 (de) 1997-02-19
ES2177642T3 (es) 2002-12-16
PT758241E (pt) 2002-10-31
NO964486D0 (no) 1996-10-22
DE69526937T2 (de) 2003-01-02
NZ283430A (en) 2000-06-23
NO310057B1 (no) 2001-05-14
HU9603042D0 (en) 1997-01-28
FI964332A0 (fi) 1996-10-28
WO1995030421A1 (en) 1995-11-16
NO964486L (no) 1996-10-22
IL113566A (en) 2002-05-23
HUT74984A (en) 1997-03-28
FI964332A (fi) 1996-10-28
US5965547A (en) 1999-10-12
JPH09512816A (ja) 1997-12-22
AU693541B2 (en) 1998-07-02
GB9408775D0 (en) 1994-06-22

Similar Documents

Publication Publication Date Title
IL113566A0 (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
HU9501752D0 (en) Application of carbamazepine and oxacarbazepine in the treatment of neurological lesions related to traumatic injuries
ZA965235B (en) Pharmaceutical and diet formulations for the prophylaxis and treatment of gastrointestinal disorders
AU685075B2 (en) Pharmaceutical composition for treating nicotine dependence
PL309594A1 (en) Apllication of rilusole in treating parkinson disease and parkinsonian syndromes
GB9317636D0 (en) Use of dexmedetomidine
GB9424766D0 (en) Pharmaceutical composition
IL115589A0 (en) Use of cck-b antagonists in pharmaceutical compositions
EP0744176A3 (de) Arzneimittel zur Hemmung von Knochenschwund
GR3034142T3 (en) Composition for the treatment or prevention of herpes
IL129267A (en) Pharmaceutical compositions comprising histamine and/or serotonin for treatment of urinary incontinence
MX9605327A (es) Uso de ciertos derivados de acido metanbisfosfonico para prevenir el aflojamiento de las protesis y la emigracion de las protesis.
IL108283A0 (en) Use of riluzole for promoting restoration following radiation
CA2183764A1 (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
ZA983211B (en) Use of mizolastine for preparing medication for the treatment of inflammation